Background {#Sec1}
==========

Heart failure (HF) affects over 500,000 people in the UK. Despite advances in medical treatment and evidence-based guidelines, patients continue to have high morbidity and poor life expectancy \[[@CR1]\]. Many patients are not treated according to guidelines and do not receive optimal doses of available medications \[[@CR2]\]. Clinicians sometimes find it difficult to recognise the early stages of worsening HF and are reluctant to increase doses of medications because of concerns about side effects such as renal failure and hypotension. Recently, biomarkers such as natriuretic peptides (B-type natriuretic peptide, BNP; or the N-terminal part of the precursor peptide of BNP, N-terminal pro-B-type natriuretic peptide, NT-proBNP, collectively referred to here as BNP), have been used as a more objective means of assessing HF severity and to prompt more appropriate titration of HF therapies.

Several randomised controlled trials (RCTs) have assessed whether using serial BNP tests to guide up-titration of medication improves clinical outcomes compared with symptom-guided therapy. The RCTs were heterogeneous in design. Most used a BNP-lowering strategy, where a BNP target was set (a single target for all patients or an individualised target) and HF medications were intensified to lower or maintain BNP at the pre-specified target. A few used a BNP-monitoring strategy, where the treating clinician was allowed to intensify HF medications using serial BNP measurements but no BNP target was set. Data from RCTs using a BNP-lowering strategy have been pooled in six aggregate data meta-analyses \[[@CR3]--[@CR8]\], one individual participant data (IPD) meta-analysis \[[@CR9]\] All of these analyses showed that patients in the BNP-lowering group had better outcomes.

We conducted a systematic review and meta-analysis of IPD and aggregate data including all RCTs, regardless of BNP-guiding strategy \[[@CR10]\]. Specific objectives were to estimate the effect of BNP-guided therapy on clinical outcomes; to estimate the extent of effect modification for key outcomes in specific subgroups; and to quantify the extent to which improved outcomes are explained by up-titration of medication and/or reduction in BNP levels. In this paper, we present an update of our meta-analysis to include data from the Guide-IT RCT \[[@CR11]\], the largest RCT to date (894 patients), which planned to recruit 1100 patients but was terminated early because of futility.

Methods {#Sec2}
=======

The protocol for the meta-analysis has been published previously \[[@CR12]\]. The study population was all patients aged over \> 18 years who were being treated for HF in primary or secondary care BNP-guided therapy or symptom-guided therapy. The primary outcome was all-cause mortality; secondary outcomes were death related to HF, cardiovascular death, all-cause hospitalisation, HF hospitalisation, adverse events, and quality of life.

Search methods for identification of studies {#Sec3}
--------------------------------------------

The search strategy is shown in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1. We searched the following electronic databases: MEDLINE (Ovid) 1950 to 6 September 2016; Embase (Ovid), 1980 to 2016, week 23; the Cochrane Library; ISI Web of Science (Citations Index and Conference Proceedings). We also searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <http://apps.who.int/trialsearch/>) and Current Controlled Trials (<http://www.isrctn.com/>) to identify trials in progress. We reviewed reference lists of all full-text papers and also searched grey literature (<http://www.opengrey.eu/> and Google Scholar).

Study selection {#Sec4}
---------------

Two review authors (MP and LD) independently triaged the titles and abstracts identified by the search and assessed the full text of all studies identified as relevant to the review. Differences in assessment by were resolved through discussion with a third author (RM). No language restriction was applied.

Establishing the collaboration {#Sec5}
------------------------------

Corresponding authors of eligible RCTs were invited to join the collaboration and were sent the IPD meta-analysis protocol with a cover letter explaining the study.

Quality assessment {#Sec6}
------------------

Two review authors (MP and LD) independently assessed the risk of bias (in accordance with recent Cochrane Collaboration guidelines \[[@CR13]\]) in each included RCT. For blinding and incomplete outcome data, risk of bias was assessed separately for pre-specified outcome domains (all-cause mortality, cause-specific mortality, adverse events, and quality of life). For incomplete outcome data and selective outcome reporting, risk of bias was assessed only in RCTs that contributed aggregate data.

Data collection and checking {#Sec7}
----------------------------

IPD were collated into a single database. All datasets were checked for consistency against the original publication reports and discrepancies were discussed and clarified with authors via email. Where authors did not provide clarification, we documented assumptions that were made regarding the data.

Statistical analysis {#Sec8}
--------------------

Meta-analysis was carried out if \> 2 RCTs reported data on the outcome of interest. All analyses were performed on an intention-to-treat basis. Hazard ratios (HR) were estimated using Cox regression modelling for each RCT. For RCTs that did not provide IPD, HR estimates from published reports \[[@CR14]\] were combined with HR estimates derived from the IPD. The HRs were combined across RCTs using random-effects meta-analysis (two stage model results using the generic inverse-variance method) \[[@CR15]\], and consistency of findings across studies was assessed using the *I*^2^ test statistic. Fixed-effects meta-analysis was also performed as a secondary analysis. Subgroup effects were determined by estimating treatment-by-covariate interaction terms for each RCT and combining the HRs across RCTs as for the main effects \[[@CR16]\]. Covariates defining subgroups were age (\< 75 vs. ≥ 75 years); gender; New York Heart Association (NYHA) class (class I/II vs class III/IV); type of HF (reduced ejection fraction, HFrEF, vs. preserved ejection fraction, HFpEF, based on LVEF, \< 40% in studies providing IPD and \< 45% in studies providing aggregate data); diabetes status, BNP level (≤ vs. \> median at baseline across all RCT participants, with separate medians calculated for RCTs that reported BNP and NTpro-BNP; cause of HF (ischaemic/non-ischaemic); previous atrial fibrillation; body mass index; systolic blood pressure. The age cut-off was chosen for consistency with other studies in elderly HF populations and to allow easy comparison with the meta-analysis by Troughton et al. \[[@CR9]\]. For the LVEF cut-off, we used the lower limit of normal LVEF (40%) used in clinical practice. This threshold of 40% was pre-specified by the study authors, although for the aggregate data studies, we had to use the cut-off of 45% specified by the researchers of the existing IPD meta-analysis \[[@CR17]\]. As for the main analysis, HR estimates from published reports \[[@CR14]\] were combined with HR estimates derived from the IPD. We calculated interactions when these were not reported from subgroup-specific HRs with 95% confidence intervals (CI) from studies using aggregate data and pooled them with interactions from additional RCTs which had contributed IPD for this study. For cardiovascular mortality and adverse events, we calculated odds ratios (OR) and 95% CI in each trial and pooled these across RCTs using random effects meta-analyses. We assessed the certainty of the evidence across each outcome measure using the GRADE approach (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) (<http://www.gradeworkinggroup.org>/.).
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For the three studies providing IPD data, the ratio of change was also calculated using the patient-specific change from baseline; after logarithmic transformation of all BNP values, the median change from baseline was calculated in each treatment group, and the ratio of the exponents of medians was calculated. All but two aggregate data studies provided median BNP values in their published report. For the two that did not (Christchurch Pilot and Signal-HF), we used the summary statistic reported (see Table [3](#Tab3){ref-type="table"}). All analyses were conducted using Stata, v14.0, using the 'ipdmetan' command \[[@CR18]\].

Sensitivity analysis {#Sec9}
--------------------

The following sensitivity analyses were conducted: restricting the analysis to RCTs that defined a BNP target; and restricting the analysis to RCTs with good allocation concealment, since this has been shown to be an important source of bias in RCT.

Checking for publication and data availability bias {#Sec10}
---------------------------------------------------

Funnel plots were used to investigate association between the precision of the effect size and effect size (which could be due to publication bias or 'small study effects') \[[@CR19]\], including and excluding RCTs for which IPD were unavailable. We included funnel plots only if a sufficient number of studies (more than 10) were available for each outcome.

Results {#Sec11}
=======

Figure [1](#Fig1){ref-type="fig"} shows the flow of studies through the review process. Full-text screening of 70 articles and unpublished studies identified 19 studies eligible for inclusion for which IPD were requested. Of these, 14 studies were included in the meta-analysis (5 IPD and 9 aggregate).Fig. 1PRISMA flow diagram

Table [1](#Tab1){ref-type="table"} shows the characteristics of the included RCTs. Of the 14 RCTs included in the meta-analysis, eight were conducted in Europe \[[@CR20]--[@CR27]\], two in New Zealand \[[@CR28], [@CR29]\], three in North America \[[@CR11], [@CR30], [@CR31]\], and one in Israel \[[@CR32]\]. One RCT (Time-CHF) published results separately for HFrEF \[[@CR26]\] and HFpEF \[[@CR33]\]. Only one RCT \[[@CR25]\] (Signal-HF, Sweden) was conducted in primary care; the other 13 were conducted in hospital HF clinics, with most of these recruiting patients during or immediately after hospitalisation for HF. Twelve RCTs used a BNP-lowering strategy \[[@CR11], [@CR20]--[@CR26], [@CR28]--[@CR31]\] and two used a BNP-monitoring strategy \[[@CR27], [@CR32]\]. Of the 12 RCTs that used a BNP-lowering strategy, nine set a single target (BNP 100--300 pg/ml; NT-proBNP 400--2200 pg/ml \[[@CR11], [@CR20], [@CR21], [@CR23], [@CR24], [@CR26], [@CR28]--[@CR30]\]), two of which used age-stratified (\< 75 years and ≥ 75 years \[[@CR24], [@CR26]\]) targets, and three set an individual BNP target (BNP level at discharge, reduction of 50% from baseline \[[@CR22], [@CR25], [@CR31]\]). Algorithms for modifying treatment in the BNP-guided therapy groups differed slightly between RCTs, but all were based on stepwise titration of therapy according to clinical guidelines. Treatment for symptom-guided therapy groups used an algorithm designed to achieve a target HF score based on signs and symptoms (e.g. Framingham HF score and NYHA class) in five RCTs \[[@CR20], [@CR26], [@CR28], [@CR29], [@CR31]\] and was entirely at the clinician's discretion in seven RCTs \[[@CR11], [@CR21]--[@CR25], [@CR30]\].Table 1Characteristics of included studies and studies eligible for inclusionStudyCountryStudy periodSettingDuration of follow-upFollow-up scheduleBNP/NT-proBNP targetClinical targetPrimary endpointTreatment algorithmStudies that provided IPDAnguita \[[@CR20]\]Spain2006--2008HF clinic18 months1, 2, 3, 6, 12, and 18 monthsBNP level \< 100 pg/mlFramingham HF score of \< 2Composite of all-cause mortality and cardiovascular hospital admissionBNP group: therapy intensified to achieve target BNP\
Control group: therapy intensified to achieve target congestion score.Northstar \[[@CR27]\]Denmark2005--2009HF clinic2.5 yearsEvery 1--3 months at the discretion of the investigatorNo set targetClinical assessmentComposite of all-cause mortality and cardiovascular hospital admissionBNP group: checklist to evaluate need for further investigation or intensification of therapy when NT-BNP was \> 30% from randomisation visit\
Control group: therapy evaluated and intensified at clinician discretionShochat \[[@CR32]\]\
Published as abstract onlyIsrael2007--2010HF clinicMedian 11 months (IQR 3--22)Every 1--2 monthsNo set targetNot knownAll-cause mortalityBNP group: therapy intensified if NT-BNP was higher by \> 30% from previous clinic visit\
Control group: not stated in abstractStarbrite \[[@CR31]\]USA2003--2005HF clinic4 monthsWeek 1 and then 1, 2, 3, and 4 monthsIndividual BNP at dischargeIndividual congestion scoreComposite of 90-day survival and hospital-free survivalBNP group: therapy intensified if BNP levels were 2 times greater than or less than the target BNP\
Control group: therapy intensified to achieve target congestion scoreUpstep \[[@CR24]\]Sweden and Norway2006--2009HF clinic≥ 12 monthsWeeks 2, 6, 10, 16, 24, 36, 48, and then every 6 months\< 75 years: BNP level \< 150 pg/ml\
≥ 75 years: BNP level \< 300 pg/mlClinical assessmentComposite of all-cause mortality, hospitalisation and worsening HFBNP group: therapy intensified according to stepwise algorithm to achieve maximally tolerated or guideline recommended target doses\
Control group: therapy intensified at clinician discretionStudies that provided aggregate data \[[@CR33]\]Christchurch Pilot \[[@CR29]\]New Zealand1998--1999HF clinic9.5 monthsEvery 3 months unless treatment targets not metNT-proBNP level \< 1700 pg/mlFramingham HF score of \< 2Total cardiovascular events (mortality, hospital admission, new HF-related outpatient episode)BNP group: therapy intensified according to stepwise algorithm to achieve target NT-BNP\
Control group: therapy intensified according to stepwise algorithm to achieve target HF scoreTime-CHF^\*^\[[@CR26], [@CR33]\]Switzerland and Germany2003--2006HF clinic18 months1, 3, 6, 12, and 18 monthsNT-proBNP less than 2× upper limit of normal: (\< 400 pg/ml for patients \< 75 yrs.; \< 800 pg/ml for patients \> = 75 years)NYHA ≤IIHospital-free survivalBNP group: therapy intensified according to stepwise algorithm to achieve target NT-BNP\
Control group: therapy intensified according to stepwise algorithm to achieve NYHA ≤IIBerger \[[@CR21]\]Austria2003--2004HF clinic15 months2 weekly, then 1, 3, 6, and 12 monthsNT-proBNP \< 2200 pg/LClinical assessmentComposite of all-cause mortality and HF re-hospitalisationBNP group: therapy intensified according to set protocol to maintain target NT-BNP\
Control group: therapy intensified at clinician discretionPrima \[[@CR22]\]Netherlands2004--2007HF clinic24 months2 weeks, 1 month, then 3 monthly for 2 yearsIndividual NT-proBNP level (lowest level at discharge or at 2 weeks follow-up)Clinical assessmentSurvival and hospital-free survivalBNP group: therapy intensified according to clinical guidelines to maintain target NT-BNP\
Control group: therapy intensified at clinician discretionSignal-HF \[[@CR25]\]Sweden2006--2009Primary care9 months1, 3, 6, and 9 monthsIndividual NT-proBNP level (reduction of 50% from baseline)Clinical assessmentComposite of survival, hospital-free survival and symptoms scoreBNP group: stepwise algorithm to increase therapy to achieve target NT-BNP\
Control group: therapy intensified at clinician discretionBattlescarred \[[@CR28]\]New Zealand2001--2006HF clinic3 years2 weekly until treatment target met then 3 monthlyNT-proBNP \< 1300 pg/mlFramingham HF score of \< 2All-cause mortalityBNP group: therapy intensified according to stepwise algorithm to achieve target NT-BNP and congestion score \< 2\
Control group: therapy intensified to achieve target congestion score \< 2Stars-BNP \[[@CR23]\]FranceNot statedHF clinic15 monthsMonths 1, 2, and 3, and then 3 monthly thereafterBNP level \< 100 pg/mlClinical assessmentComposite of HF mortality or HF hospitalisationBNP group: therapy intensified according to clinical guidelines to maintain target NT-BNP\
Control group: therapy intensified at clinician discretionProtect \[[@CR30]\]USA2006--2010HF clinicAt least 6 monthsAs required to meet treatment target and then 3 monthly (for max 12 months)NT-proBNP ≤ 1000 pg/mlClinical assessmentComposite of worsening HF, HF hospitalisation and cardiovascular eventsBNP group: therapy intensified according to clinical guidelines to maintain target NT-BNP\
Control group: therapy intensified at clinician discretionGuide-IT \[[@CR11]\]USA2013--2016HF clinic15 monthsInitial visits at 2 and 6 weeks and then every 3 months. A follow-up visit 2 weeks after any therapy adjustmentNT-proBNP \< 1000 pg/mlClinical assessmentComposite of cardiovascular death and HF hospitalisationBNP group: therapy intensified at clinician discretion but in line with clinical guidelines to achieve target NT-BNP\
Control group: therapy intensified at clinician discretion but in line with clinical guidelinesEligible studies that did not provide IPD or aggregate dataKaravidas \[[@CR45]\]\
Published as abstract onlyGreeceNot statedNot stated12 monthsNot statedNot stated but likely no set targetClinical assessmentNot clear. Composite of all-cause mortality cardiovascular hospitalisation?Not statedHome \[[@CR46]\]\
Clinical trial registration onlyIreland, UK, Australia and Canada2011--2014Not stated6 months1, 3, and 6 monthsNot stated but likely no set targetNot statedAverage number of 'hard' events per subject (HF mortality, hospitalisation for HF, unplanned outpatient episodes for decompensated HF (including change in diuretic therapy)BNP group: therapy intensified at clinician discretion using BNP information\
Control group: As above but without the BNP informationOptima \[[@CR47]\]\
Published as poster onlyCzech RepublicNot statedNot statedNot statedNot statedNot stated but likely a BNP lowering strategyClinical assessmentComposite of cardiovascular mortality, HF hospitalisation and outpatient episodes of worsening HF requiring an increase in diuretic by at least 50%BNP group: therapy intensified to 'normalise' plasma BNP levels.\
Control group: therapy intensified at clinician discretion according to guidelines.Koshkina et al. \[[@CR48]\]\
Published as abstract onlyRussian FederationNot statedHF clinicMean (SD) 10 ± 2.5 monthsNot statedNT-proBNP \< 1000 pg/ml or at least 50% of the initialClinical assessmentTotal cardiovascular eventsNot statedEx Improve CHF \[[@CR49]\]\
Study ongoingCanada2007--ongoingHF clinicMinimum 12 monthsNot statedNo set targetClinical assessmentComposite of all-cause mortality and HF hospitalisationBNP group: therapy intensified at clinician discretion using BNP information\
Control group: As above but without the BNP information^\*^Time-CHF reported results separately for patients with heart failure with reduced ejection fraction (HFrEF) \[[@CR26]\] and patients with heart failure with preserved ejection fraction (HFpEF) \[[@CR33]\]

In the IPD dataset, the mean age of participants was 70 years, three quarters of patients were men, most patients had LV systolic dysfunction (median LVEF, 30%) and over 80%) had NYHA class II or III (Table [2](#Tab2){ref-type="table"}). The patients in RCTs providing aggregate data had similar characteristics (Table [3](#Tab3){ref-type="table"}).Table 2Baseline characteristics of patients in included studiesStudyNumber of patients (BNP-guided/symptom-guided)Age (years)\
Mean (SD)Patients ≥ 75 years\
*n* (%)Male\
*n* (%)LVEF (%)\
Median (IQR)^\*^LVEF ≥ 40%^\*\*^*n* (%)NYHA class I/II/III/IVSmoking status (non-smoker/ex-smoker/current smoker)Body mass index, kg/m^2^(mean, SD)Systolic BP, mmHG (mean, SD)Diastolic BP, mmHG (mean, SD)Studies that provided IPDAnguita \[[@CR20]\]60 (30/30)69 (10)18/54 (33%)41/60 (68%)40 (26, 65)27/55 (49%)3/38/19/037/7/16------Northstar \[[@CR27]\]407 (199/208)73 (8)186/407 (46%)309/407 (76%)30 (25, 35)36/402 (9%)80/268/59/047/114/11026 (5)127 (19)73 (12)Shochat \[[@CR32]\]120 (60/60)70 (11)50/120 (42%)103/120 (86%)30 (25, 35)11/75 (15%)1/55/41/1634/0/40--125 (21)74 (11)Starbrite \[[@CR31]\]130 (65/65)60 (15)24/130 (18%)91/130 (70%)20 (15, 25)0/129 (0%)----29 (8)111 (21)69 (13)Upstep \[[@CR24]\]268 (140/128)71 (10)105/268 (39%)196/268 (73%)--0/268 (0%)0/83/147/37--27 (5)----All985 (494/491)70 (11)383/979 (39%)740/985 (75%)30 (20, 35)74/929 (8%)84/444/266/53118/121/16627 (5)124 (21)73 (12)Studies that provided aggregate data^§^Christchurch\
Pilot \[[@CR29]\]69 (33/36)70 (10)24/69 (35%)53/69 (7%)27 (8)0/69 (0%)\~ 70% (class II)----127 (SD not provided)76 (SD not provided)Time-CHF HFrEF \[[@CR26]\]499 (251/248)76 (8)289/499 (58%)327/499 (66%)30 (8)0/499 (0%)371/499 (74%) (≥ class III)--25 (4)119 (19)--Time-CHF HFpEF \[[@CR33]\]123 (59/64)80 (7)--42/123 (34%)56 (6)123/123 (100%)0/21/82/20--27 (5)136 (23)74 (12)Berger \[[@CR21]\]188 (92/96)71 (12)88/188 (47%)147/188 (78%)29 (9)11/188 (6%)All patients class III--IV----121 (18)72 (12)Prima \[[@CR22]\]345 (174/171)72 (12)166/345 (48%)197/345 (57%)36 (14)93/345 (27%)37/234/74166/105/74--118 (21)69 (11)Signal-HF \[[@CR25]\]252 (127/125)78 (7)184/252 (73%)180/252 (71%)32 (8)5/252 (2%)0/154/96/0----134 (22)74 (12)Battlescarred \[[@CR28]\]242 (121/121)74 (9)138/242 (57%)157/242 (65%)39 (15)90/242 (37%)24/162/52/4----124 (23)71 (13)Stars-BNP \[[@CR23]\]220 (110/110)66 (5)--127/220 (58%)31 (8)----101/220 (current smokers)------Protect \[[@CR30]\]151 (75/76)63 (14)38/151 (25%)127/151 (84%)27 (9)0/151 (0%)129/151 (85%) (class II--III)92/48/1129 (6)110 (16)66 (9)Guide-IT \[[@CR11]\]894 (446/448)62 (51 to 70) in BNP-guided group, 64 (54--72) in symptom-guided group^\*\*\*^161/894 (18%)608/894 (68%)25 (19 to 30)^\*\*\*^All had LVEF ≤ 40%59/447/358/17 of 881----114 (102 to 128) in BNP-guided group, 114 (101 to 128) in symptom-guided group^\*\*\*^--^\*^Mean (SD) for studies providing aggregate data. ^\*\*^≥ 45% for studies providing aggregate data. ^\*\*\*^Median and interquartile range, ^§^ data from original reports or IPD meta-analysis by Troughton et al. \[[@CR9]\] and Brunner La-Rocca et al. \[[@CR17]\]. Missing data: Age, Anguita---6 patients with missing data; LVEF, Anguita---5 patients with missing data; Northstar---5 patients with missing data; Shochat---45 patients with missing data; Starbrite---1 patient with missing data; BMI, Northstar---4 patients with missing data; Starbrite---45 patients with missing data; Upstep---3 patients with missing data; SBP, Shochat---37 patients with missing data; Starbrite---1 patient with missing data; DBP, Northstar---1 patient with missing data; Shochat---37 patients with missing data; Starbrite---1 patient with missing dataTable 3BNP/NT-proBNP (pg/ml) levels at baseline and end of follow-up in the BNP-guided therapy group and symptom-guided therapy groupBNP/NT-proBNP (pg/ml)^\*^Studies that provided IPDStudies that provided aggregate dataAnguita \[[@CR20]\]Northstar \[[@CR27]\]Shochat \[[@CR32]\]Starbrite \[[@CR31]\]Upstep \[[@CR34]\]Christchurch Pilot \[[@CR29]\]Time-CHF \[[@CR26], [@CR33]\]Berger \[[@CR21]\]Prima \[[@CR22]\]Signal-HF \[[@CR25]\]Battlescarred \[[@CR28]\]Stars-BNP \[[@CR23]\]Protect \[[@CR30]\]Guide-It \[[@CR11]\]*n* = 60*n* = 407*n* = 120*n* = 130*n* = 268*n* = 69*n* = 499*n* = 278*n* = 345*n* = 252*n* = 364*n* = 220*n* = 151BNP guided-therapy:Baseline^\*^34 (7, 83)1884 (1385, 2955)1905 (1099, 4488)453 (221, 1135)601 (346, 946)1839HFrEF\
3998\
(2075, 7220)\
HFpEF\
2210\
(1514--4081)2216 (355, 9649)2961\
(discharge)\
(1383, 5144)2661 (2.1)2012 (516, 10,233)352 (260)23442568End of follow-up8 (3, 83)--1765 (476, 3966)413 (111, 894)--1169----252923601610 (6 months)284\
(180)\
(3 months)11251209Difference2 (−31, 28)--−81 (− 1273, 512)−14 (− 461, 248)--− 670----− 432 (− 1392, 297)−301−402− 6812191359% change from baseline:6%--−4%−3%--−36%----−15%− 11%− 20%− 19%−52%− 53%Symptom-guided therapy:Baseline^\*^22 (5, 104)2042 (1390, 3560)1569 (784, 4919)441 (189, 981)609 (376, 952)2127HFrEF\
4657\
(2455, 7520)\
HFpEF\
2191\
(1478, 4890)2469\
(355, 18,487)2936 (discharge)\
(1291, 5525)2429 (2.1)1996 (425, 6588)--19462678End of follow-up39\
(6, 104)--1822\
(618, 4489)471\
(236, 1180)--2102----236420671537\
(6 months)--18441397Difference4 (−20, 46)--73 (− 554, 1245)51 (− 130, 288)--−25----− 572 (− 1329, 434)− 362− 459--1021281% change from baseline:18%--5%12%--−1%----−19.5%− 15%−23%--−5%− 48%^\*^Median (IQR) reported for all studies except Christchurch Pilot (type of summary statistic not reported), Protect (median only reported), Signal-HF (geometric mean reported), and Stars-BNP (mean reported)For all studies, BNP values at discharge from randomisation visit were used (assumed values at discharge reported if not stated otherwise in trial reports)For Northstar and Upstep, BNP values at the end of follow-up were not available. For the remaining studies providing IPD, the difference between the baseline and end of follow-up was calculated as the median (IQR) change from baseline across patients. For studies providing aggregate data, the change from baseline was calculated by taking the average BNP at end of follow-up from the average BNP at baseline.For all studies, the % change from baseline is calculated as the average difference as a percentage of the average baseline BNP

Eleven out of the 14 included RCTs (79%) were rated as having a high risk of bias across at least one risk domain (Additional file [2](#MOESM2){ref-type="media"}: Appendix 2). The main factor that contributed to ratings of high risk of bias was the lack of blinding (of participants and care-giving clinicians). None of the funnel plots generated for the outcomes with more than 10 studies contributing data suggested marked asymmetry (Additional file [3](#MOESM3){ref-type="media"}: Appendix 3). There were no significant issues identified with the IPD datasets provided. The overall quality of the body of evidence for all outcomes varied from low to very low (Table [4](#Tab4){ref-type="table"}).Table 4Summary of findings tableSerial B-type natriuretic peptide (BNP) blood testing to guide up-titration of medication compared to symptom-guided up-titration of medication in patients with heart failure (HF)Patient or population: patients with heart failure (HF)\
Setting: secondary care\
Intervention: serial B-type natriuretic peptide (BNP) blood testing to guide up-titration of medication\
Comparison: symptom-guided up-titration of medicationOutcome\
No. of participants (studies)Relative effect (95% CI)Anticipated absolute effects (95% CI)CertaintyWhat happensWithout serial B-type natriuretic peptide (BNP) blood testing to guide up-titration of medicationWith serial B-type natriuretic peptide (BNP) blood testing to guide up-titration of medicationDifferenceAll-cause mortality follow up: range 3 to 30 months\
No. of participants: 3691 (13 RCTs)HR 0.87 (0.71 to 1.01)19.9%17.5% (14.6 to 20.1)2.3% fewer (5.3 fewer to 0.2 more)⨁⨁◯◯ Low^a,b^BNP-guided therapy may result in little to no difference in all-cause mortality.Death related to HF follow up: range 12 to 15 months\
No. of participants: 488 (2 RCTs)Two studies reported death related to HF. There were no significant differences between the BNP-guided therapy and the symptom-guided therapy groups in either study (3/110 vs. 9/110, respectively, and 21/140 vs. 16/128, respectively).⨁◯◯◯Very low ^a,b,c^It is uncertain whether BNP-guided therapy prevents death related to HF because the quality of the evidence is very low.Cardiovascular death follow up: range 9 to 23 months\
No. of participants: 1909 (5 RCTs)OR 0.88 (0.67 to 1.16)13.7%12.3% (9.6 to 15.6)1.4% fewer (4.1 fewer to 1.9 more)⨁⨁◯◯\
Low ^a,b^BNP-guided therapy may lead to little or no difference in cardiovascular death.All-cause hospitalisation follow up: range 3 to 30 months\
No. of participants: 984 (7 RCTs)HR 0.97 (0.85 to 1.10)57.2%56.1% (51.4 to 60.7)1.1% fewer (5.8 fewer to 3.5 more)⨁⨁◯◯ Low^a,b^BNP-guided therapy may result in little or no difference in all-cause hospitalisation.HF hospitalisation follow up: range 9 to 30 months\
No. of participants: 2655 (8 RCTs)HR 0.81 (0.68 to 0.98)34.1%28.6% (24.7 to 33.5)5.4% fewer (9.4 fewer to 0.6 fewer)⨁◯◯◯ Very low^a,b,d^It is uncertain whether BNP-guided therapy reduces hospital admissions for HF because the quality of evidence is very low.Adverse events follow up: range 9 to 18 months\
No. of participants: 2055 (5 RCTs)OR 1.29 (1.04 to 1.60)24.4%29.4% (25.1 to 34.1)5.0% more (0.7 more to 9.7 more)⨁⨁◯◯ Low^a,b^BNP-guided therapy may lead to an increase in adverse events.Quality of life follow up: range 10 to 30 months\
No. of participants: 1884 (6 RCTs)Six studies reported data on QoL (five used the Minnesota Living with Heart Failure Questionnaire and one used SF-36) in their published report. Data could not be combined in a meta-analysis because changes in QoL were reported differently in each study. Only one study reported a significant improvement in QoL in the BNP-guided therapy group vs. symptom guided therapy group; five reported no difference between groups. Three additional studies included a statement in their published report saying that that there was no difference in QoL between groups and one included a statement saying that results of QoL analyses were not reported in the manuscript.⨁◯◯◯ Very low^a,b,c^It is uncertain whether BNP-guided therapy improves quality of life because the quality of the evidence is very low.\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*CI* confidence interval; *HR* hazard ratio; *OR* odds ratioGRADE Working Group grades of evidenceHigh certainty: we are very confident that the true effect lies close to that of the estimate of the effectModerate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially differentLow certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effectVery low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect^a^None of the RCTs were blinded (either patients or healthcare professionals) so at risk of bias due to deviations from intended interventions (performance bias)^b^Most RCTs did not include patients with HF with preserved ejection fraction (HFpEF). Women and patients \> = 75 years were also under-represented^c^Narrative synthesis was conducted; estimates are not precise^d^*I*^2^ statistic (46%) suggests moderate heterogeneity

Primary outcome {#Sec12}
---------------

Across 13 RCTs that reported all-cause mortality, 17% (320/1845) of patients in the BNP-guided therapy group, and 20% (367/1846) of patients in the symptom-guided therapy group died during follow up. Median follow-up in the five RCTs that provided IPD was 18 months (IQR 8--27). BNP-guided therapy did not reduce the hazard of death from any cause compared with symptom-guided therapy (HR 0.87, 95% CI 0.75 to 1.01) (Fig. [2](#Fig2){ref-type="fig"}). There was no significant heterogeneity between RCTs. The sensitivity analysis excluding the two RCTs that did not use a BNP-lowering strategy did not alter this finding (HR 0.86, 95% CI 0.73 to 1.01). The sensitivity analysis combining the effect estimates from three RCTs that were judged to have had good allocation concealment showed no difference in the hazard of death between groups (HR 0.93, 95% CI 0.60--1.44).Fig. 2All-cause mortality. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD, aggregate data, and overall. Time-CHF reported results separately for patients with heart failure with reduced ejection fraction (HFrEF) \[[@CR26]\] and patients with heart failure with preserved ejection fraction (HFpEF) \[[@CR33]\]. HR for all-cause mortality was not available for the Protect study \[[@CR30]\]. The HR and 95% CI from Guide-It \[[@CR11]\] was adjusted for age, sex, left ventricular ejection fraction, NT-proBNP, and the presence of diabetes mellitus. Note: weights are from random effect analysis

Secondary outcomes {#Sec13}
------------------

Five RCTs provided aggregate data on numbers of patients with cardiovascular death; these showed that 12% (120/963) of patients in the BNP-guided therapy group and 14% (130/946) of patients in the symptom-guided therapy group died because of a cardiovascular cause. BNP-guided therapy did not reduce the odds of cardiovascular death (OR 0.88, 95% CI 0.66--1.16) (Fig. [3](#Fig3){ref-type="fig"}). Only two studies provided aggregate data on death due to HF; Stars-BNP \[[@CR23]\] and Upstep \[[@CR24]\] showed that 3% (3/110) and 15% (21/140), respectively, of patients in the BNP-guided therapy group, and 8% (9/110) and 12.5% (16/128), respectively, of patients in the symptom-guided therapy group had a death directly attributable to HF.Fig. 3Cardiovascular mortality. Odds ratio (OR) with 95% confidence intervals (CI) for five aggregate data studies. Note: weights are from random effect analysis

Across six RCTs with data on all-cause hospitalisation, 58% (285/493) of patients in the BNP-guided therapy group had at least one hospital admission, compared with 57% (281/491) of patients in the symptom-guided therapy group. BNP-guided therapy did not reduce the hazard of all-cause hospitalisation (HR 0.97, 95% CI 0.85--1.10) (Fig. [4](#Fig4){ref-type="fig"}). The results did not differ in the analysis restricted to RCTs that used a BNP-lowering strategy (HR 0.95, 95% CI 0.81--1.11).Fig. 4All-cause hospitalisation. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD, aggregate data, and overall. HR for all-cause hospitalisation was only available for Time-CHF (HFrEF and HFpEF \[[@CR33]\]). Note: weights are from random effect analysis.

Across eight RCTs that provided data on numbers of patients with HF hospitalisation, there were 392/1328 patients (29.5%) who had at least one hospitalisation for HF in the BNP-guided therapy group, compared with 452/1327 patients (34%) in the symptom-guided therapy group. BNP-guided therapy led to a lower hazard of hospitalisation due to HF (HR 0.81, 95% CI 0.68--0.98) (Fig. [5](#Fig5){ref-type="fig"}**)**. The results did not differ in the sensitivity analysis restricted to RCTs that set a BNP target (HR 0.77, 95% CI 0.64--0.99). The sensitivity analysis with respect to allocation concealment was not performed because only two RCTs were classified as having a low risk of bias. In all meta-analyses (for primary and secondary outcomes), the results from the fixed-effects meta-analyses did not differ from the random-effects meta-analyses results.Fig. 5Heart failure (HF) hospitalisation. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD, aggregate data, and overall. Note: weights are from random effect analysis

Subgroup analyses {#Sec14}
-----------------

Stratum-specific treatment effects are reported in Additional file [4](#MOESM4){ref-type="media"}: Appendix 4. For all-cause mortality, there was a significant interaction between treatment strategy and age (*p* = 0.034, 11 RCTs), and treatment strategy and LVEF (*p* = 0.026, 10 RCTs). BNP-guided therapy was beneficial for trial participants \< 75 years old (HR 0.70, 95% CI 0.53--0.92) but not for trial participants ≥ 75 years old (HR 1.07, 95% CI 0.84--1.37). Similarly, BNP-guided therapy was beneficial for trial participants with HFrEF (HR 0.84, 95% CI 0.71--0.99), but not those with HFpEF (HR 1.33, 95% CI 0.83--2.11). This effect was largely driven by one RCT (Time-CHF); excluding this from the analysis attenuated the protective effect in the lower LVEF subgroup was attenuated (HR 0.89, 95% CI 0.73--1.06).

There were no significant interactions between treatment strategy and any of the other covariates investigated in the subgroup analyses for any of the outcomes (*p* \> 0.05). However, for age and LVEF, stratum-specific estimates for the secondary outcomes (all-cause and HF hospitalisations) were consistent with those for all-cause mortality, suggesting a protective effect of BNP-guided therapy.

Changes in BNP from baseline to end of follow-up {#Sec15}
------------------------------------------------

BNP levels at baseline and end of follow-up were available for nine RCTs (Table [3](#Tab3){ref-type="table"}). In six of these \[[@CR11], [@CR22], [@CR25], [@CR28]--[@CR30]\], BNP levels decreased in both the BNP-guided therapy group and the symptom-guided therapy group. There was no consistent relationship between the change in BNP from baseline between groups and the HR for all-cause mortality (Fig. [6](#Fig6){ref-type="fig"}). RCTs that provided evidence for a relationship (i.e. studies with the most extreme HRs for mortality favouring BNP guided-therapy and in which BNP fell substantially more in the BNP-guided group than in the symptom-guided group) provided least weight in the meta-analysis. Calculating the relative change between groups using IPD (for studies that provided IPD) provided even less evidence for a relationship.Fig. 6Relationship between hazard ratios (HR) for all-cause mortality and the ratio of change in BNP/NT-proBNP from baseline between the BNP-guided therapy group and symptom-guided therapy group. Filled circles represent the ratio of the change calculated using aggregate data, and open circles represent the ratio of the change calculated using IPD; the change in the position on the *x*-axis shows the differences between the two analyses methods, while the position on the *y*-axis remains the same

Medication changes {#Sec16}
------------------

We could not combine IPD and aggregate data to investigate the association between changes in medication and outcomes because changes in medication were inconsistently reported in studies on both IPD studies and aggregate data studies.

Adverse events and discontinuation {#Sec17}
----------------------------------

None of the IPD studies provided data on adverse events. Five aggregate data studies \[[@CR11], [@CR25], [@CR26], [@CR29], [@CR30], [@CR33]\] provided data on total number of adverse events by group; these showed that 29% (293/1023) of patients in the BNP-guided therapy group and 14% (130/946) of patients in the symptom-guided therapy group experienced an adverse event. Adverse events were significantly more frequent in the BNP-guided therapy group compared with that in symptom-guided therapy group (OR 1.29, 95% CI 1.04 to 1.60) (Fig. [7](#Fig7){ref-type="fig"}). Adverse events most commonly reported included renal impairment and hypotension, one study reported additional adverse events such as hyper/hypokalaemia, anaemia, fever, dizziness, gastrointestinal bleeding, respiratory infection, and syncope.Fig. 7Total adverse events. Odds ratios (OR) and 95% confidence intervals (CI) for five aggregate data studies. Note: weights are from random effect analysis

Quality of life (QoL) {#Sec18}
---------------------

None of the IPD studies provided QoL data both at baseline and follow-up. QoL data were available from aggregate data in six studies (including the published reports of two IPD studies: Northstar \[[@CR27]\] and Upstep \[[@CR24]\]). These could not be pooled in a meta-analysis because changes in QoL were reported differently in each study. Five studies assessed QoL using the Minnesota Living with Heart Failure questionnaire \[[@CR22], [@CR26]--[@CR28], [@CR30]\], and one study \[[@CR24]\] assessed QoL using the SF-36 questionnaire. Northstar \[[@CR27]\] reported no change in QoL in either group \[median (IQR) change 0 (− 6 to 2) and 0 (− 5 to 6) between baseline and end of study visit (6 months to 4.5 years), in the BNP-guided therapy group and symptom-guided therapy group, respectively\]. Three of the aggregate data studies showed that QoL improved significantly and similarly in both groups: Battlescarred \[[@CR28]\]: mean (SD) 36.5 (22.7) and 36.6 (23.1) at baseline vs. 28.8 (21.6) and 26.5 (22.0) at 12 months in the BNP-guided therapy group and symptom-guided therapy group, respectively; Prima \[[@CR22]\] (median (IQR), 47 (34 to 62) and 48 (36 to 60) at baseline vs. 20 (3--36) and 23 (10--38) at 12 months follow up, in the BNP-guided therapy group and symptom-guided therapy group, respectively; Time-CHF \[[@CR26]\] (mean (SD), 38.3 (20.2) and 40.2 (20.3) at baseline vs. 27.7 (17.90 and 27.0 (18.6) at 12 months, in the BNP-guided therapy group and symptom-guided therapy group, respectively. Only one of the aggregate data studies showed a greater improvement in the BNP-guided therapy group compared with the symptom-guided therapy group \[Protect \[[@CR30]\] (median improvement between baseline and follow-up at 12 months, − 10.0 vs. − 5.0, *p* = 0.05, in the BNP-guided therapy group and symptom-guided therapy group, respectively\]. The Upstep study \[[@CR24]\] assessed quality of life using the SF-36 questionnaire (eight domains) and found no significant differences between groups \[[@CR34]\]. The remaining studies did not provide data on QoL; three studies included a statement to say that the change/improvement in QoL was similar in both groups \[[@CR20], [@CR25], [@CR29]\], one study did not mention quality of life \[[@CR31]\], while the Guide-It study included a statement saying that the results of QoL analyses were not reported in their manuscript \[[@CR11]\].

Discussion {#Sec19}
==========

Main findings {#Sec20}
-------------

Our meta-analysis, including data for up to 3968 patients with HF (1982 randomised to BNP-guided therapy and 1986 randomised to symptom-guided therapy) suggests that BNP-guided therapy may result in little to no difference in all-cause or cardiovascular mortality. It is uncertain whether BNP-guided therapy reduces hospital admissions for HF because the quality of evidence is very low. BNP-guided therapy may lead to an increase in adverse events. A previous IPD meta-analysis by Troughton et al. \[[@CR9]\] (which excluded the subgroup of participants with HFpEF from the Time-CHF RCT) showed a 18% reduction in the hazard of death from any cause (HR 0.82, 95% CI 0.67--1.00) and a 26% reduction in the hazard of hospital admission for HF (HR 0.74, 95% CI 0.60--0.90), but the authors did not assess the quality of evidence and therefore reached different conclusions. The results from our subgroup analyses showed more benefit of BNP-guided therapy in patients \< 75 years old and patients with HFrEF, which is consistent with the analyses reported by Troughton et al. \[[@CR9]\] and Brunner La-Rocca et al. \[[@CR17]\].

Was the treatment effect a result of decreasing BNP or up-titration of medication? {#Sec21}
----------------------------------------------------------------------------------

The observed benefit in the BNP-guided therapy group could not be attributed to changes in BNP levels during follow-up between groups (Fig. [5](#Fig5){ref-type="fig"}). There was no consistent relationship between the relative BNP change from baseline between groups and the hazard ratio for all-cause mortality. Although the smaller RCTs showed a relatively large BNP change between groups and lower hazard ratios, this was not reflected in the larger RCTs that provided most weight in the meta-analysis. The meta-analysis by Troughton et al. \[[@CR9]\] showed that BNP levels decreased by 35% in the BNP-guided therapy group and 32% in the symptom-guided therapy group. Similarly, the Guide-IT RCT showed a 53% decrease in the BNP-guided therapy group and a 48% decrease in the symptom-guided therapy group.

Although we could not determine whether and how HF medication doses changed during follow up, the meta-analysis by Troughton et al. \[[@CR9]\] showed no differences in medication dose changes between groups, except for a modest increase in doses of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB) in the BNP-guided therapy group (8.4% increase, 3.4 to 13, vs. − 1.2% decrease, − 6.1 to 3.7 in the symptom-guided therapy group). While treatment with ACEi and ARB according to guidelines has been shown to reduce the risk of death and hospitalisation in both RCTs and large registries \[[@CR35]--[@CR38]\]; over 89% of patients in the RCTs were already receiving these medications \[[@CR9]\], so it is unclear whether the relatively small dose increases in the BNP-guided therapy group were responsible for the benefit observed. Furthermore, the Guide-IT RCT showed modest intensification of HF medications, including ACEi and ARB, in both groups.

BNP-lowering vs. BNP-monitoring strategy {#Sec22}
----------------------------------------

In our meta-analysis, we included all RCTs that used serial BNP measurements to guide HF therapy, regardless of the guiding strategy used. There were several reasons for this. First, we aimed to provide realistic treatment effect estimates given that, in the absence of established guidelines describing how treatment should be guided by BNP, clinicians are likely to use BNP levels to manage their patients in diverse ways (e.g. to check the status quo, to lower BNP as much as possible, or to a target). Second, the two strategies are not fundamentally dissimilar, since both will prompt a patient review with intensification of medications if considered appropriate. Third, RCTs evaluating BNP-lowering were themselves heterogeneous in design, treatment strategies (in both the BNP group and the control group), and BNP target. Finally, we wished to include all studies in order to avoid publication related biases, data availability bias, and reviewer selection bias \[[@CR39]--[@CR41]\]; previous meta-analyses did not publish a priori protocols. These biases can lead to meta-analyses being biased towards more favourable treatment effects \[[@CR41], [@CR42]\] and have been highlighted as a potential problem in meta-analyses that use IPD \[[@CR41]\]. The exclusion of two studies that did not target a specific BNP level \[[@CR27], [@CR32]\] did not alter the findings of our meta-analysis.

Strengths and limitations of this study {#Sec23}
---------------------------------------

Our meta-analysis has several strengths. We systematically identified all RCTs evaluating BNP-guided therapy in HF patients, included all RCTs for which IPD or aggregate data were available, and conducted meta-analyses in accordance with a pre-specified protocol \[[@CR12]\] and published guidelines. There was no evidence of publication bias or a small study effect (for all-cause mortality and HF hospitalisation, which had data from more than 10 studies).

The main limitation was our inability to obtain IPD from most of the RCTs included in the meta-analysis by Troughton et al. \[[@CR9]\], which constrained our sub-group analyses. Other limitations arose from the design of the RCTs: heterogeneity in how BNP-guided therapy and symptom-guided therapy was administered; restricted eligibility (mainly younger patients with HFrEF and without co-morbidities), limiting the applicability of the results to the broader HF population; and the potential for bias because most RCTs did not blind clinicians or patients to treatment allocation. This lack of blinding means that co-interventions affecting outcomes could have been initiated by either the doctors or the participants themselves, conditional on their knowledge of the allocation. Also, despite combining results from 14 RCTs, the pooled sample size (up to 3968 patients with HF) was relatively small in comparison with sample sizes in other meta-analyses in this patient population (some of which included over 13,000 patients \[[@CR43]\]); therefore, chance may explain some of the apparently significant findings. Finally, data on adverse events were not reported consistently and therefore only five studies contributed data for a meta-analysis.

Implications for clinicians and policy-makers {#Sec24}
---------------------------------------------

Our meta-analysis has shown that BNP-guided treatment in hospital cardiology clinics significantly reduced HF hospitalisation but not all-cause or cardiovascular mortality. However, this conclusion may not be applicable to other health settings and HF patients who were not eligible (older patients with HFpEF). By contrast, across many European countries, cardiologists do not lead the management of patients with HF, and about half of all patients have HFpEF. Patients with HFpEF tend to be older with more comorbidities than their HFrEF counterparts. There are significant gaps and variation in the medical care of HF patients, and there is evidence that not all patients are receiving optimal treatment according to guidelines \[[@CR44]\]. It therefore appears more prudent in the first instance to ensure adherence to guidelines for managing HF before recommending BNP-guided therapy.

Conclusion {#Sec25}
==========

The conclusions about the efficacy of BNP-guided therapy are uncertain because the findings are of borderline statistical significance and the overall quality of the evidence varied from low to very low. We could not identify an optimal BNP monitoring strategy and no group of researchers has defined one. Therefore, consensus about an optimal BNP monitoring strategy should urgently be sought, preferably through a formal process involving cardiologists, general practitioners, and patients. It is striking that BNP levels decreased, and HF medications increased in both the BNP-guided therapy and symptom-guided therapy groups in the RCTs; this strongly suggests that HF management outside the RCTs was suboptimal. The reasons why not all patients receive care according to guidelines is unclear; understanding why may require qualitative research with different types of practitioner who care for HF patients.

Additional files
================

 {#Sec26}

Additional file 1:Appendix 1. Literature search. (DOCX 18 kb) Additional file 2:Appendix 2. Risk of bias. (DOCX 132 kb) Additional file 3:Appendix 3. Funnel plots. (DOCX 41 kb) Additional file 4:Appendix 4. Subgroup analyses. (DOCX 851 kb)

ACEi

:   Angiotensin-converting enzyme inhibitors

ARB

:   Angiotensin II receptor blockers

BNP

:   B-type natriuretic peptide
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